318 related articles for article (PubMed ID: 21550109)
1. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells.
Wang XX; Li YB; Yao HJ; Ju RJ; Zhang Y; Li RJ; Yu Y; Zhang L; Lu WL
Biomaterials; 2011 Aug; 32(24):5673-87. PubMed ID: 21550109
[TBL] [Abstract][Full Text] [Related]
2. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.
Zhou J; Zhao WY; Ma X; Ju RJ; Li XY; Li N; Sun MG; Shi JF; Zhang CX; Lu WL
Biomaterials; 2013 May; 34(14):3626-38. PubMed ID: 23422592
[TBL] [Abstract][Full Text] [Related]
3. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
4. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.
Yu Y; Wang ZH; Zhang L; Yao HJ; Zhang Y; Li RJ; Ju RJ; Wang XX; Zhou J; Li N; Lu WL
Biomaterials; 2012 Feb; 33(6):1808-20. PubMed ID: 22136714
[TBL] [Abstract][Full Text] [Related]
6. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer.
Zhang Y; Li RJ; Ying X; Tian W; Yao HJ; Men Y; Yu Y; Zhang L; Ju RJ; Wang XX; Zhou J; Chen JX; Li N; Lu WL
Mol Pharm; 2011 Feb; 8(1):162-75. PubMed ID: 21062083
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells.
Zhang L; Yao HJ; Yu Y; Zhang Y; Li RJ; Ju RJ; Wang XX; Sun MG; Shi JF; Lu WL
Biomaterials; 2012 Jan; 33(2):565-82. PubMed ID: 21983136
[TBL] [Abstract][Full Text] [Related]
8. Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity.
Song YF; Liu DZ; Cheng Y; Liu M; Ye WL; Zhang BL; Liu XY; Zhou SY
Sci Rep; 2015 Nov; 5():16125. PubMed ID: 26530454
[TBL] [Abstract][Full Text] [Related]
9. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
[TBL] [Abstract][Full Text] [Related]
10. Mitochondria-targeted delivery of doxorubicin to enhance antitumor activity with HER-2 peptide-mediated multifunctional pH-sensitive DQAsomes.
Shi M; Zhang J; Li X; Pan S; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
Int J Nanomedicine; 2018; 13():4209-4226. PubMed ID: 30140154
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Subcellular Trafficking of Resveratrol Using Mitochondriotropic Liposomes in Cancer Cells.
Kang JH; Ko YT
Pharmaceutics; 2019 Aug; 11(8):. PubMed ID: 31434345
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol induces apoptosis associated with mitochondrial dysfunction in bladder carcinoma cells.
Lin X; Wu G; Huo WQ; Zhang Y; Jin FS
Int J Urol; 2012 Aug; 19(8):757-64. PubMed ID: 22607368
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma.
Li XY; Zhao Y; Sun MG; Shi JF; Ju RJ; Zhang CX; Li XT; Zhao WY; Mu LM; Zeng F; Lou JN; Lu WL
Biomaterials; 2014 Jul; 35(21):5591-604. PubMed ID: 24726749
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of targeting tumor with folate-based amphiphilic multifunctional stabilizer for resveratrol nanosuspensions.
Wang L; Liu Y; Zhao J; Li C; Zhou Y; Du J; Wang Y
Colloids Surf B Biointerfaces; 2017 Dec; 160():462-472. PubMed ID: 28988124
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial targeting nanodrugs self-assembled from 9-O-octadecyl substituted berberine derivative for cancer treatment by inducing mitochondrial apoptosis pathways.
Song J; Lin C; Yang X; Xie Y; Hu P; Li H; Zhu W; Hu H
J Control Release; 2019 Jan; 294():27-42. PubMed ID: 30445003
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
18. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals.
Men Y; Wang XX; Li RJ; Zhang Y; Tian W; Yao HJ; Ju RJ; Ying X; Zhou J; Li N; Zhang L; Yu Y; Lu WL
Int J Nanomedicine; 2011; 6():3125-37. PubMed ID: 22163164
[TBL] [Abstract][Full Text] [Related]
20. Fabrication of paclitaxel hybrid nanomicelles to treat resistant breast cancer via oral administration.
Dian LH; Hu YJ; Lin JY; Zhang JY; Yan Y; Cui YN; Su ZB; Lu WL
Int J Nanomedicine; 2018; 13():719-731. PubMed ID: 29440897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
